Approval after phase I: Ceritinib runs the three-minute mile

Oncologist

Volumn 19, Issue 6, 2014, Pages 577-578

  Chabner, Bruce A ^a  

^a MASSACHUSETTS GENERAL HOSPITAL CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CERITINIB; CRIZOTINIB; IMATINIB; PONATINIB; PYRIMIDINE DERIVATIVE; SULFONE;

CHRONIC MYELOID LEUKEMIA; DIARRHEA; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; EDITORIAL; HUMAN; HYPERTRANSAMINASEMIA; INTERSTITIAL LUNG DISEASE; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TUMOR BIOPSY; TUMOR GROWTH; FOOD AND DRUG ADMINISTRATION; NEOPLASMS; UNITED STATES;

CLINICAL TRIALS, PHASE I AS TOPIC; DRUG APPROVAL; HUMANS; NEOPLASMS; PYRIMIDINES; SULFONES; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84901923871     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2014-0143     Document Type: Editorial

References (4)

1. Chabner BA. The oncologic four-minute mile. The Oncologist 2001;6:230-232.
2. Ou SI, Bartlett CH, Mino-Kenudson M et al. Crizotinib for the Treatment of ALK-rearranged non-small cell lung cancer: A s uccess story to usher in the second decade of molecular targeted therapy in oncology. The Oncologist 2012;17:1351-1375.
3. Shaw AT, Kim DW, Mehra R et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014;370:1189-1197.
4. Groarke JD, Cheng S, Moslehi J. Cancer-drug discovery and cardiovascular surveillance. N Engl J Med 2013;369:1779-1781.